Calcific Aortic Valve Disease
Conditions
Interventions
case group:no
control group:no
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Case group: Signed and dated informed consent form; 2.Case group: Meet the diagnostic criteria for aortic valve calcification: Based on Doppler echocardiography and two-dimensional echocardiography findings, meeting one or more of the following imaging features: 1) Irregular thickening of the aortic valve leaflets with locally enhanced echoes, suggesting calcific changes; 2) Stiff leaflets with visible commissural fusion and restricted valve opening; 3) Continuous-wave Doppler showing normal or only mildly elevated peak transvalvular flow velocity (= that of the aortic root echo reflection; 3.Case group: And meet the surgical indications for aortic valve replacement (meeting any of the following conditions): 1) Patients with calcific aortic stenosis, aortic valve area = 6.7 kPa (50 mmHg), accompanied by left ventricular ejection fraction 60 mmHg, peak transvalvular velocity > 5 m/s) and an expected surgical mortality rate < 1%; 4) Patients with aortic stenosis who have high-risk factors for rapid progression of valve disease (e.g., advanced age, significant calcification, concomitant coronary artery disease), including some asymptomatic patients with severe aortic stenosis; 5) Patients requiring coronary artery bypass grafting for coronary artery disease and presenting with mild aortic stenosis, but with evidence suggesting possible rapid progression of valve disease (e.g., moderate to severe valve calcification). 4.Control group: Meet the criteria for valve replacement due to aortic valve prolapse and undergo surgery: 1) Moderate to severe aortic valve prolapse meets the criteria for valve replacement/repair; 2) Individuals without the above-mentioned pathological features of aortic valve calcification; or recipients who meet the criteria for heart transplantation; 5.Control group: or recipients who meet the criteria for heart transplantation. 6.Control group: Signed and dated informed consent form;
Exclusion criteria
Exclusion criteria: 1. Valvular lesions caused by rheumatic heart disease; 2. Infective endocarditis or other active, acute inflammatory diseases; 3. Syphilis, Takayasu's arteritis; 4. Marfan syndrome or other definitively diagnosed connective tissue diseases; 5. Cases where clinical or imaging data are incomplete and cannot meet the requirements for research analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Abundance of differentially expressed proteins;Abundance of differentially expressed gene transcripts; | — |
Secondary
| Measure | Time frame |
|---|---|
| Aortic valve peak transvalvular velocity (Vmax);Concentration of candidate biomarker in the serum; | — |
Countries
China
Contacts
Public ContactYang Ke
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed